MedTrace Logo

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects

NCT01626976 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-03-13

No results posted yet for this study

Summary

This is the first-in-human study for an oral investigational compound, PF-06282999, in order to assess its safety, tolerability and pharmacokinetics in humans across a wide range of dose levels.

Conditions

  • Healthy

Interventions

DRUG

PF-06282999

Solution, doses range from 20 to 200 mg, single dose

DRUG

Placebo

Solution, single dose

DRUG

PF-06282999

Methylcellulose suspension, doses range 125 to 500 mg, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Methylcellulose or simethicone suspension, 500 mg dose, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Simethicone or methylcellulose suspension, up to 1500 mg, single dose

DRUG

Placebo

suspension, single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01626976 on ClinicalTrials.gov